In the observational, prospective CCTA study of Hjuler Boesgaard and colleagues, 204 asymptomatic patients with T2D (55 receiving liraglutide as part of clinical care, 149 not) underwent baseline and 1-year CCTA [9]
To view or add a comment, sign in More Relevant Posts Today we announced positive topline results from partner Shanghai Jeyou Pharmaceuticals Phase 2 trial evaluating RPT904 (JYB1904) as a monotherapy for chronic spontaneous urticaria (CSU)
Endogenous Roles The compound performs three main functions: neutralizing reactive oxygen species, conjugating xenobiotics for Phase II detoxification (via glutathione S-transferases), and recycling other antioxidants such as vitamins C and E
This article explores GLP-1 drugs through the lens of integrative medicine, combining the best of conventional, natural, and lifestyle-based therapies
Saxenda Saxenda shares the same active ingredient as Victoza (liraglutide)